GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ImmunoPrecise Antibodies Ltd (NAS:IPA) » Definitions » Revenue

IPA (ImmunoPrecise Antibodies) Revenue : $17.68 Mil (TTM As of Jul. 2024)


View and export this data going back to 2011. Start your Free Trial

What is ImmunoPrecise Antibodies Revenue?

ImmunoPrecise Antibodies's revenue for the three months ended in Jul. 2024 was $3.84 Mil. Its revenue for the trailing twelve months (TTM) ended in Jul. 2024 was $17.68 Mil. ImmunoPrecise Antibodies's Revenue per Share for the three months ended in Jul. 2024 was $0.14. Its Revenue per Share for the trailing twelve months (TTM) ended in Jul. 2024 was $0.68.

Warning Sign:

ImmunoPrecise Antibodies Ltd revenue per share has been in decline over the past 3 years.

During the past 12 months, the average Revenue per Share Growth Rate of ImmunoPrecise Antibodies was 5.00% per year. During the past 3 years, the average Revenue per Share Growth Rate was -7.00% per year. During the past 5 years, the average Revenue per Share Growth Rate was -0.80% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate using Revenue per Share data.

During the past 13 years, ImmunoPrecise Antibodies's highest 3-Year average Revenue per Share Growth Rate was 22.90% per year. The lowest was -7.00% per year. And the median was 6.20% per year.


ImmunoPrecise Antibodies Revenue Historical Data

The historical data trend for ImmunoPrecise Antibodies's Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ImmunoPrecise Antibodies Revenue Chart

ImmunoPrecise Antibodies Annual Data
Trend Dec14 Dec15 Apr17 Apr18 Apr19 Apr20 Apr21 Apr22 Apr23 Apr24
Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 10.01 14.34 15.33 15.33 17.93

ImmunoPrecise Antibodies Quarterly Data
Oct19 Jan20 Apr20 Jul20 Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24 Apr24 Jul24
Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.31 4.49 4.64 4.72 3.84

Competitive Comparison of ImmunoPrecise Antibodies's Revenue

For the Biotechnology subindustry, ImmunoPrecise Antibodies's Revenue, along with its competitors' market caps and Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


ImmunoPrecise Antibodies's Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, ImmunoPrecise Antibodies's Revenue distribution charts can be found below:

* The bar in red indicates where ImmunoPrecise Antibodies's Revenue falls into.



ImmunoPrecise Antibodies Revenue Calculation

Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.

Revenue for the trailing twelve months (TTM) ended in Jul. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $17.68 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


ImmunoPrecise Antibodies  (NAS:IPA) Revenue Explanation

In ranking the predictability, companies with more consistent revenue and earnings growth are ranked high with predictability.

Peter Lynch categorized companies according to their revenue growth:


Slow Grower: Inflation < 10-Year Revenue Growth Rate < 10%:
Stalwart: 10% < 10-Year Revenue Growth Rate < 20%:
Fast Grower: 10-Year Revenue Growth Rate > 20%:

His favorite companies are stalwart, those growing between 10-20% a year.

Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.


Be Aware

Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.


ImmunoPrecise Antibodies Revenue Related Terms

Thank you for viewing the detailed overview of ImmunoPrecise Antibodies's Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


ImmunoPrecise Antibodies Business Description

Traded in Other Exchanges
Address
3204 - 4464 Markham Street, Victoria, BC, CAN, V8Z 7X8
ImmunoPrecise Antibodies Ltd is a biotechnology company that leverages multi-omics modeling and complex artificial intelligence through a series proprietary and patented technologies. The company owns an integrated end-to-end suite of capabilities to support the development of therapeutic antibodies and are known for solving very complex industry challenges.